Rani Therapeutics (RANI) Revenue & Revenue Breakdown
Rani Therapeutics Revenue Highlights
0
Latest Revenue (Q)
$1.71M
Rani Therapeutics Revenue by Period
Rani Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2025-12-31 | - | -100.00% |
| 2024-12-31 | $1.03M | 100.00% |
| 2023-12-31 | - | 100.00% |
| 2022-12-31 | - | -100.00% |
| 2021-12-31 | $2.72M | 488.10% |
| 2020-12-31 | $462.00K | -52.81% |
| 2019-12-31 | $979.00K | - |
Rani Therapeutics generated - in revenue during NA 2025, up -100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Rani Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2026-03-31 | $1.71M | 16.91% |
| 2025-12-31 | $1.46M | 100.00% |
| 2025-09-30 | - | 100.00% |
| 2025-06-30 | - | -100.00% |
| 2025-03-31 | $172.00K | -83.27% |
| 2024-12-31 | $1.03M | 100.00% |
| 2024-09-30 | - | 100.00% |
| 2024-06-30 | - | 100.00% |
| 2024-03-31 | - | 100.00% |
| 2023-12-31 | - | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | -100.00% |
| 2021-06-30 | $1.96M | 159.39% |
| 2021-03-31 | $756.00K | 260.00% |
| 2020-12-31 | $210.00K | 94.44% |
| 2020-09-30 | $108.00K | 80.00% |
| 2020-06-30 | $60.00K | -27.71% |
| 2020-03-31 | $83.00K | - |
Rani Therapeutics generated $1.71M in revenue during Q1 2026, up 16.91% compared to the previous quarter, and up 166.15% compared to the same period a year ago.
Rani Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| SGMO | Sangamo Therapeutics | $57.80M | $1.44M |
| IPHA | Innate Pharma | $51.90M | $16.56M |
| TNXP | Tonix Pharmaceuticals | $13.11M | $6.88M |
| MOLN | Molecular Partners | $7.04M | $2.74M |
| MIST | Milestone Pharmaceuticals | $1.55M | $238.00K |
| ELTX | Elicio Therapeutics | - | - |
| CRBP | Corbus Pharmaceuticals | - | - |
| RANI | Rani Therapeutics | - | $1.71M |
| CRDF | Cardiff Oncology | - | - |